Suven Life Sciences Limited (SUVEN) Price & Analysis

Compare

3 Followers

SUVEN Stock Chart & Stats

₹165.00

₹14.56(11.52%)

At close: Jan 08 4:00 PM EST

₹165.00

₹14.56(11.52%)

Day’s Range― - ―

52-Week Range₹102.70 - ₹303.00

Previous CloseN/A

Volume2.87M

Average Volume (3M)14.83K

Market Cap

₹34.77B

Enterprise Value₹34.27B

Total Cash (Recent Filing)₹600.05M

Total Debt (Recent Filing)₹0.00

Price to Earnings (P/E)―

Beta1.77

Next Earnings

Apr 30, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-4.48

Shares Outstanding227,474,210

10 Day Avg. Volume16,308

30 Day Avg. Volume14,834

Financial Highlights & Ratios

PEG Ratio-0.31

Price to Book (P/B)24.25

Price to Sales (P/S)400.69

P/FCF Ratio-14.36

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low Financial LeverageEssentially no debt in FY2025 materially lowers near-term solvency and interest-risk. This durable balance-sheet buffer gives management time to stabilize operations or restructure without immediate refinancing pressure, supporting survival through multi-quarter cash burn.

Fee-based Contract Research ModelA fee-based contract research business serves pharma/biotech clients and is structurally durable due to ongoing outsourcing of discovery work. Established service revenues and milestone billing can produce repeat business and a diversified client base when demand normalizes.

Specialized Discovery CapabilitiesSpecialized medicinal-chemistry and discovery support are high-skill, technical services that create competitive differentiation and higher switching costs. These capabilities support deeper client relationships and the potential for higher-margin, sticky engagements over time.

Bears Say

Negative Gross Profit & MarginsNegative gross profit and a -24.2% net margin indicate a breakdown in unit economics from pricing, costs or adverse mix. Persistent negative margins will erode capital and require structural changes—cost cuts, pricing renegotiation, or a different service mix—to restore durable profitability.

Persistent Cash BurnConsistently deeply negative operating and free cash flow show the business is not self-funding. Ongoing cash burn increases funding risk, constrains reinvestment, and makes long-term viability dependent on either sustained operational improvement or external financing.

Equity Erosion / Weakening Capital BaseSharp equity decline signals value erosion and weaker capital buffers, reducing the company's financial flexibility. Lower equity heightens dilution risk if capital is raised and leaves the firm more vulnerable to industry shocks or prolonged revenue weakness.

Suven Life Sciences Limited News

Suven Life Sciences Opens Special Window for Re-Lodgment of Physical Share Transfers

Suven Life Sciences Limited ( ($IN:SUVEN) ) just unveiled an update. Suven Life Sciences has notified stock exchanges...

4d ago

SUVEN

Suven Life Sciences Attributes Share Price Surge to Market Speculation

Suven Life Sciences Limited ( ($IN:SUVEN) ) has shared an announcement. Suven Life Sciences Limited has responded to...

17d ago

SUVEN

SUVEN FAQ

What was Suven Life Sciences Limited’s price range in the past 12 months?

Suven Life Sciences Limited lowest stock price was ₹102.70 and its highest was ₹303.00 in the past 12 months.

What is Suven Life Sciences Limited’s market cap?

Suven Life Sciences Limited’s market cap is ₹34.77B.

When is Suven Life Sciences Limited’s upcoming earnings report date?

Suven Life Sciences Limited’s upcoming earnings report date is Apr 30, 2026 which is in 66 days.

How were Suven Life Sciences Limited’s earnings last quarter?

Suven Life Sciences Limited released its earnings results on Jan 29, 2026. The company reported -₹4.481 earnings per share for the quarter, missing the consensus estimate of N/A by -₹4.481.

Is Suven Life Sciences Limited overvalued?

According to Wall Street analysts Suven Life Sciences Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Suven Life Sciences Limited pay dividends?

Suven Life Sciences Limited pays a Annually dividend of ₹1.382 which represents an annual dividend yield of N/A. See more information on Suven Life Sciences Limited dividends here

What is Suven Life Sciences Limited’s EPS estimate?

Suven Life Sciences Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Suven Life Sciences Limited have?

Suven Life Sciences Limited has 227,474,210 shares outstanding.

What happened to Suven Life Sciences Limited’s price movement after its last earnings report?

Suven Life Sciences Limited reported an EPS of -₹4.481 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.758%.

Which hedge fund is a major shareholder of Suven Life Sciences Limited?

Currently, no hedge funds are holding shares in IN:SUVEN

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Suven Life Sciences Limited

Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders in India, the United States, Europe, and internationally. The company engages in drug discovery and development of new chemical entities (NCEs) in central nervous system therapies. Its product candidates include SUVN-502 for the treatment of Alzheimer's disease and neuropsychiatric symptoms; SUVN-G3031, a potent and selective histamine H3 receptor inverse agonist for the treatment of sleep and cognitive disorders; and SUVN-911, a novel, potent, and selective a4ß2 nicotinic acetylcholine receptor antagonist for the treatment of depressive disorders. The company is also developing SUVN-D4010, a potent, selective, and orally bio-available and brain penetrant 5-HT4 receptor partial agonist for the treatment of cognitive disorders; SUVN-I6107 for the treatment of cognitive disorders and schizophrenia; SUVN-M8036 for the treatment of psychiatric disorders; and SUVN-D1044 for the treatment of gastrointestinal disorders. The company was formerly known as Suven Pharmaceuticals Pvt. Ltd. and changed its name to Suven Life Sciences Limited in 2003. The company was incorporated in 1989 and is headquartered in Hyderabad, India. Suven Life Sciences Limited is a subsidiary of Jasti Property and Equity Holdings Private Limited.